{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-003682","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2026-05-11T21:10:17+00:00","discovered_at":"2026-05-11T21:12:00.363058+00:00","generated_at":"2026-05-11T21:13:33.308464+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Odyssey Health's sublicense deal for BreastCheck cancelled by NeuRX due to breach of Davion contract","bullets":["NeuRX revoked its Oct 2025 agreement with Odyssey to sublicense Davion's BreastCheck product, effective immediately.","NeuRX admits it lacked legal right to sublicense without Davion's written consent; Davion would have declined approval.","Cancellation follows notice that NeuRX breached representations and warranties in the definitive agreement.","Davion demands Odyssey withdraw public statements that it holds a BreastCheck sublicense."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-003682","json":"https://secwatch.observer/filing/0001683168-26-003682.json","markdown":"https://secwatch.observer/filing/0001683168-26-003682.md","text":"https://secwatch.observer/filing/0001683168-26-003682.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316826003682/0001683168-26-003682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316826003682/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T21:13:33.308464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}